Ridaforolimus.
Ridaforolimus.
复制标题
DOI：
10.2165/11586010-000000000-00000
复制
发表时间：
2010-01-01
期刊：
影响因子：
3
通讯作者：
中科院分区：
文献类型：
--
作者：
Ridaforolimus （AP23573; MK 8669）是西罗莫司的类似物和用于治疗癌症的哺乳动物雷帕霉素靶点的小分子抑制剂。该化合物的静脉注射和口服制剂正在进行临床试验，用于治疗软组织和骨肉瘤。该药物在欧盟和美国处于治疗肉瘤的III期开发阶段，在美国和世界其他市场处于治疗乳腺癌、子宫内膜癌、非小细胞肺癌和前列腺癌的II期开发阶段。本文综述了该药物的关键发展里程碑和治疗试验。
Ridaforolimus (AP23573; MK 8669) is an analog of sirolimus and a small molecule inhibitor of the mammalian target of rapamycin for the treatment of cancer. Both intravenous and oral formulations of the compound are being tested in clinical trials for the treatment of soft-tissue and bone sarcomas. It is in phase III development for sarcoma in the EU and US, and phase II for breast cancer, endometrial cancer, non-small cell lung cancer, and prostate cancer in the US and other markets in the world. This review discusses the key development milestones and therapeutic trials of this drug.